Previous 10 | Next 10 |
Calliditas Therapeutics to Attend Investor Conferences in March PR Newswire STOCKHOLM , March 1, 2024 /PRNewswire/ -- Calliditas Therapeutics AB (Nasdaq: CALT) and (Nasdaq Stockholm: CALTX) ("Calliditas"), a commercial biopharma company focused on rare diseases t...
2024-02-29 16:06:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
2024-02-21 17:46:07 ET Calliditas Therapeutics AB (publ) (CALT) Q4 2023 Earnings Call Transcript February 21, 2024, 08:30 AM ET Company Participants Renee Aguiar-Lucander - CEO Richard Philipson - CMO Maria Tornsen - President, North America Fredrik Johansson...
Vimeo Inc. (VMEO) is expected to report $-0.01 for Q4 2023 Heineken N.V ADR (HEINY) is expected to report for Q4 2023 American States Water Company (AWR) is expected to report $0.53 for Q4 2023 NextPlay Technologies Inc. (NXTP) is expected to report for Q3 2024 Inseego Corp. (INSG...
Calliditas Year-end report, January - December 2023 PR Newswire STOCKHOLM , Feb. 21, 2024 /PRNewswire/ -- Calliditas Therapeutics AB (Nasdaq Stockholm: CALTX) 2023: Full approval for TARPEYO in the US; a year of successes "In December we wer...
Invitation to the presentation of Calliditas´ Year-end report January - December 2023 PR Newswire STOCKHOLM , Feb. 14, 2024 /PRNewswire/ -- Calliditas' Year-end report for January - December 2023 will be published in Swedish and English on Wednesday ...
Calliditas provides patent update PR Newswire STOCKHOLM , Feb. 13, 2024 /PRNewswire/ -- Calliditas Therapeutics AB (Nasdaq: CALT, Nasdaq Stockholm: CALTX) ("Calliditas") today announced that the United States Patent and Trademark Office (USPTO) issued patent no...
2024-01-28 10:20:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
2024-01-25 15:30:27 ET Summary Vera Therapeutics, Inc. stock price soared over 35% today as it announced positive results from the open label extension of its Phase 2b ORIGIN clinical trial for atacicept in IgA nephropathy. The company's stock is up over 160% in the past year and ...
2024-01-14 12:00:24 ET More on CRISPR, GSK, etc. Pfizer Is Part Of The 2024 Healthcare Sector Rally Cohort Impact Of Gene Therapies And Casgevy On Crispr AG And The Industry CRISPR Therapeutics AG (CRSP) 42nd Annual J.P. Morgan Healthcare Conference (Transcript) ...
News, Short Squeeze, Breakout and More Instantly...
Calliditas Therapeutics AB Company Name:
CALT Stock Symbol:
NASDAQ Market:
NEW YORK, Aug. 01, 2024 (GLOBE NEWSWIRE) -- Calliditas Therapeutics AB (Nasdaq: CALT) (“Calliditas”) Chief Executive Officer, Renée Aguiar-Lucander, will participate in a panel during this year’s Women in Nephrology (WIN) Leadership Conference in Los Angeles, CA on Augus...
Calliditas partner STADA receives European Commission decision for full approval of Kinpeygo® for the treatment of IgA Nephropathy PR Newswire STOCKHOLM , July 26, 2024 /PRNewswire/ -- Calliditas Therapeutics AB (Nasdaq: CALT, Nasdaq Stockholm: CALTX) ("Ca...
Calliditas announces positive TRANSFORM Phase 2b topline data in primary biliary cholangitis PR Newswire STOCKHOLM , July 26, 2024 /PRNewswire/ -- Calliditas Therapeutics AB (NASDAQ: CALT) ( STOCKHOLM : CALTX) ("Calliditas") today announced that the Pha...